Format

Send to

Choose Destination
BMJ. 2019 Aug 20;366:l4609. doi: 10.1136/bmj.l4609.

Clostridioides difficile: diagnosis and treatments.

Guery B1,2,3,4, Galperine T5,2, Barbut F6,7,4.

Author information

1
Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland benoit.guery@chuv.ch.
2
French Group of Faecal Microbiota Transplantation.
3
European Study Group on Host and Microbiota Interactions.
4
European Study Group on Clostridium difficile.
5
Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland.
6
National Reference Laboratory for Clostridium difficile, Paris, France.
7
INSERM, Faculté de Pharmacie de Paris, Université Paris Descartes, Paris, France.

Abstract

Clostridioides difficile (formerly Clostridium) is a major cause of healthcare associated diarrhea, and is increasingly present in the community. Historically, C difficile infection was considered easy to diagnose and treat. Over the past two decades, however, diagnostic techniques have changed in line with a greater understanding of the physiopathology of C difficile infection and the use of new therapeutic molecules. The evolution of diagnosis showed there was an important under- and misdiagnosis of C difficile infection, emphasizing the importance of algorithms recommended by European and North American infectious diseases societies to obtain a reliable diagnosis. Previously, metronidazole was considered the reference drug to treat C difficile infection, but more recently vancomycin and other newer drugs are shown to have higher cure rates. Recurrence of infection represents a key parameter in the evaluation of new drugs, and the challenge is to target the right population with the adapted therapeutic molecule. In multiple recurrences, fecal microbiota transplantation is recommended. New approaches, including antibodies, vaccines, and new molecules are already available or in the pipeline, but more data are needed to support the inclusion of these in practice guidelines. This review aims to provide a baseline for clinicians to understand and stratify their choice in the diagnosis and treatment of C difficile infection based on the most recent data available.

PMID:
31431428
DOI:
10.1136/bmj.l4609
[Indexed for MEDLINE]

Conflict of interest statement

Declaration of interests We have read and understood the BMJ policy on declaration of interests and declare the following interests: BG reports personal fees, and non-financial support from Astellas, personal fees and non-financial support from MSD TG reports personal fees, and non-financial support from Astellas, personal fees and non-financial support from MSD FB reports grants, personal fees, and non-financial support from Astellas, personal fees from Pfizer, grants, personal fees and non-financial support from MSD Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center